News Focus
News Focus
Followers 67
Posts 2892
Boards Moderated 0
Alias Born 04/22/2022

Re: dstock07734 post# 757163

Saturday, 03/29/2025 11:59:25 AM

Saturday, March 29, 2025 11:59:25 AM

Post# of 820951
dstock07734,

In my view, acquiring the Roswell commercial license may be just as significant as the UCLA DCVax-L license…

The two most relevant aspects of NWBO’s prospective value are:

⭐️ Combos with other agents that are already commercialized worldwide. (For one example, consider how the global commercial success of PD-1 blockade technology may impact dendritic cell platforms!) 🤔

⭐️ Multiple Patent-Fortified DC Platforms

Moffitt has interesting connections to Roswell and the two are collaborating on at least one active clinical trial today. At a minimum, Moffitt’s work has provided solid proof of concept for the value/need for DC technology in oncology, and I think we may soon learn more about the relationship between Moffitt and Roswell in the context of NWBO.

It is great to see the collaborative/cooperative efforts that have advanced DC technology from the Steinman era into a new era of combo therapies. NCI-designated cancer centers and multiple government agencies have worked together in developing dendritic cell-based platform technologies, which are now beginning to demonstrate efficacy in combo with established therapies that are already successful in the expanding global immunotherapy market.







Bullish
Bullish

Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News